• Cellares to offer proof-of-concept manufacturing for a key BMS CAR-T cell remedy
• Cellares’ proprietary Cell Shuttle is a cost-efficient, dependable, totally automated, and extremely scalable manufacturing answer
• Bristol Myers Squibb is the newest firm to hitch Cellares’ TAP program to guage potential advantages in assembly affected person demand, decreasing course of failure charges, decreasing manufacturing prices, and accelerating scale-out

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 /PRNewswire/ — Cellares, the primary Integrated Development and Manufacturing Organization (IDMO) devoted to scientific and industrial-scale cell remedy manufacturing, introduced that world biopharmaceutical firm and cell remedy developer Bristol Myers Squibb (NYSE: BMY) has joined its Technology Adoption Partnership (TAP) program. As a part of the settlement, the pharma chief will enter right into a proof-of-concept switch course of for the manufacture of one in all its CAR-T cell therapies, utilizing Cellares’ automated manufacturing platform, the Cell Shuttle.

Cellares’ TAP program is a quick and low-risk alternative for cell remedy builders to undertake the corporate’s automated manufacturing expertise for merchandise of their pipeline. Bristol Myers Squibb is leveraging this program to guage the automated manufacturing course of and produce comparability knowledge confirming the Cell Shuttle as a viable, cost-efficient, and scalable manufacturing answer for cell therapies. Through its TAP program, Cellares is working with main cell remedy builders to implement the Cell Shuttle as a scientific and commercial-stage GMP manufacturing answer at its IDMO Smart Factories.

“We’re pleased to welcome Bristol Myers Squibb to the TAP program, and we look forward to demonstrating the ease and efficacy of transferring one of BMS’s cell therapy process onto the Cell Shuttle in the months to come,” stated Cellares CEO Fabian Gerlinghaus. “By combining integrated automation with a high-throughput platform, the Cell Shuttle offers unrivaled scalability for the cell therapy industry, while improving quality and lowering COGS.”

Cellares’ versatile manufacturing expertise helps each autologous and allogeneic cell remedy processes and roughly 90% of cell remedy modalities. Manual processes will be automated and tech-transferred onto Cellares’ automated Cell Shuttle platform in solely six months by way of the corporate’s Technology Adoption Partnership (TAP) program. Under the TAP program, taking part cell remedy builders can tech-transfer their cell remedy processes onto a Cell Shuttle at any stage – throughout pre-clinical growth, within the clinic, or after regulatory approval. Thanks to automation, standardization, and software-defined manufacturing (SDM), each tech switch thereafter is instantaneous, to some other Cell Shuttle in some other IDMO Smart Factory anyplace on this planet.

Please go to cellares.com/partnering/ to study extra in regards to the TAP program and request a gathering with a enterprise growth consultant.

About Cellares

Cellares is the primary Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 strategy to mass manufacturing the dwelling medicine of the twenty first century. The firm is each creating and working built-in applied sciences for cell remedy manufacturing to speed up entry to life-saving cell therapies. The firm’s Cell Shuttle integrates all of the applied sciences required for all the manufacturing course of in a versatile and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will probably be deployed in Cellares’ Smart Factories around the globe to satisfy complete affected person demand for cell therapies at world scale. Partnering with Cellares permits teachers, biotechs, and pharma corporations to speed up drug growth and scale out manufacturing, decrease course of failure charges, decrease manufacturing prices, and meet world affected person demand.

The firm is headquartered in South San Francisco, California with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The firm is backed by world-class traders and has raised over $355 million in financing.

For extra details about Cellares, please go to cellares.com.

Media Contact:
[email protected]

Logo – https://mma.prnewswire.com/media/1503684/Cellares_Logo.jpg

SOURCE Cellares